An observational study in Myocardial Injury and Coronary Artery Disease, sponsored by Second Hospital of Jilin University. Not yet recruiting at 1 site in China. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Second Hospital of Jilin University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.
Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 187th largest by planned enrollment of the 218 observational ones that give a count, is one of 54 that started in 2026, is one of 219 observational ones, reaches primary completion later than 123 of the 209 other live ones, and was the 510th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 18–80
BrosMed Medical Co., Ltd · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in China, United States, Australia and 1 more country
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 21 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
543 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 24 · Phase 4 66
First in 2000; this study’s year is marked. 54 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 307 across the 324 interventional studies, 720 across the 218 observational. Of the 187 that completed or were terminated, 24 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 543 have an industry lead sponsor. The 10 most frequent:
Second Hospital of Jilin University is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Second Hospital of Jilin University has 4 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
32 of the studies in Coronary Artery Disease with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05175274Phase 3Qingdao Central HospitalColchicine Use for Primary Prevention of Coronary Artery Disease | 2027-03-01 |
| NCT07439133Phase 3Sinotau Pharmaceutical GroupComparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) | 2027-06 |
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
| NCT06845410Peking Union Medical College HospitalClinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study | 2026-12 |
| NCT06917664China National Center for Cardiovascular DiseasesTreatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease | 2026-12 |
Add all 32 to your calendar (.ics) → With an account.
Among the 543 studies in Coronary Artery Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Perioperative myocardial injury (PMI) following coronary artery bypass grafting (CABG) is associated with postoperative morbidity, mortality, and long-term outcomes. High-sensitivity troponin assays and cardiac MRI offer reliable diagnostic tools for PMI, but evidence regarding optimal diagnostic thresholds and perioperative imaging strategy is limited. This prospective clinical study aims to determine the incidence of perioperative myocardial injury using multimodal assessments including high-sensitivity troponin, electrocardiogram, echocardiography, cardiac MRI, and perioperative cardiovascular events.
Adult patients diagnosed with unstable angina and scheduled to undergo isolated coronary artery bypass grafting (CABG) at the Second Hospital of Jilin University. All participants receive routine perioperative clinical evaluations. The study includes patients aged 21 years or older who provide written informed consent and have had no major cardiovascular events within the previous 6 months. Patients with severe organ dysfunction, pregnancy, or contraindications to cardiac MRI are excluded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A prospective cohort of adult patients undergoing elective or urgent coronary artery bypass grafting. Participants will undergo perioperative evaluation including hs-troponin testing, ECG, echocardiography, and cardiac MRI to assess perioperative myocardial injury.
Diagnostic Test: High-Sensitivity Troponin · Diagnostic Test: Cardiac MRI
High-sensitivity troponin levels are measured preoperatively, predischarge, and at 6-month follow-up to assess perioperative myocardial injury.
A diagnostic assessment panel including high-sensitivity troponin testing, electrocardiography, echocardiography, and cardiac magnetic resonance imaging performed during the perioperative period.
Incidence of Perioperative Myocardial Injury (PMI)
Perioperative myocardial injury defined by elevation of high-sensitivity troponin above the 99th percentile upper reference limit together with new myocardial injury detected by cardiac MRI or supportive ECG/echocardiographic changes. PMI is assessed using laboratory testing and imaging performed preoperatively, within 48 hours post-CABG, and at discharge.
Time frame: Within 48 hours post-CABG
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jun 2027, 11 months later.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 11 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Hospital of Jilin University